Price Alert

Arvinas Inc. (ARVN)

NASDAQ: ARVN · Real-Time Price · USD

7.73

0.20 (2.66%)

At close: Sep 24, 2025, 3:59 PM

7.76

0.37%

After-hours: Sep 24, 2025, 07:35 PM EDT

2.66% (1D)

Bid	7.54
Market Cap	567.52M
Revenue (ttm)	372.8M
Net Income (ttm)	-72.6M
EPS (ttm)	-1.01
PE Ratio (ttm)	-7.65
Forward PE	-2.61
Analyst	Buy
Dividends	n/a

Ask	8
Volume	3,301,658
Avg. Volume (20D)	1,858,298
Open	7.57
Previous Close	7.53
Day's Range	7.38 - 7.83
52-Week Range	5.90 - 29.61
Beta	2.39
Ex-Dividend Date	n/a

About ARVN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ARVN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ARVN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Arvinas Inc. is scheduled to release its earnings on Oct 29, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-15.51%

Arvinas shares are trading lower after the company... Unlock content with Pro Subscription

3 months ago

+8.82%

Arvinas shares are trading higher after the company announced its submission of an NDA to the FDA for Vepdegestrant

News

1 week ago · reuters.com

Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party

Drug developer Arvinas said on Wednesday it will grant commercialization rights of an experimental breast cancer treatment it was developing with Pfizer to a third party.

2 weeks ago · seekingalpha.com

Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Arvinas, Inc. (NASDAQ:ARVN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants John Houston - Chairperson, CEO & President Noah Berkowitz - Chief M...

1 month ago · seekingalpha.com

Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript

Arvinas, Inc. (NASDAQ:ARVN ) Q2 2025 Earnings Call August 6, 2025 8:00 AM ET Company Participants Andrew R. Saik - CFO & Treasurer Angela M.

1 month ago · zacks.com

Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates

Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $0.49 per share a year ago.